Quantitative in situ detection of phosphoproteins in fixed tissues using quantum dot technology

Journal of Histochemistry and Cytochemistry

Volumn 57, Issue 7, 2009, Pages 701-708

  Bodo, Juraj ^a   Durkin, Lisa ^a   Hsi, Eric D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

FLT3; Immunofluorescence; Phosphoprotein; pSTAT5; Quantum dot

Indexed keywords

CD135 ANTIGEN; GLYCOGEN SYNTHASE KINASE 3BETA; NANOCRYSTAL; PHOSPHOPROTEIN; PROTEIN KINASE; QUANTUM DOT; STAT5 PROTEIN; ANTINEOPLASTIC AGENT; ENZASTAURIN; FIXATIVE; FLT3 PROTEIN, HUMAN; FORMALDEHYDE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INDOLE DERIVATIVE;

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW BIOPSY; CALIBRATOR; CELL SPECIFICITY; CELL TYPE; CLINICAL LABORATORY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TISSUE FIXATION; TISSUE MICROARRAY; TUMOR XENOGRAFT; ANIMAL; BONE MARROW; CALIBRATION; CANCER TRANSPLANTATION; CELL LINE; COLON TUMOR; DRUG ANTAGONISM; GENETICS; METABOLISM; PHOSPHORYLATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; CALIBRATION; CELL LINE; COLONIC NEOPLASMS; FIXATIVES; FMS-LIKE TYROSINE KINASE 3; FORMALDEHYDE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INDOLES; LEUKEMIA, MYELOID, ACUTE; MICE; MUTATION; NEOPLASM TRANSPLANTATION; PHOSPHOPROTEINS; PHOSPHORYLATION; QUANTUM DOTS; STAT5 TRANSCRIPTION FACTOR; TISSUE ARRAY ANALYSIS; TISSUE FIXATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 67651177529     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/jhc.2009.953547     Document Type: Article

References (39)

1. Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, Tubbs RR, et al. (2007) Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol 31:233-239
2. Andre F, Nahta R, Conforti R, Boulet T, Aziz M, Yuan LX, Meslin F, et al. (2008) Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol 19:315-320
3. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, Powis G (2005) Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 11:4338-4340
4. Birle DC, Hedley DW (2006) Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Mol Cancer Ther 5:2494-2502
5. Bodo J, Jakubikova J, Chalupa I, Bartosova Z, Horakova K, Floch L, Sedlak J (2006) Apoptotic effect of ethyl-4-isothiocyanatobuta-noate is associated with DNA damage, proteasomal activity and induction of p53 and p21cip1/waf1. Apoptosis 11:1299-1310
6. Bunting KD, Xie XY, Warshawsky I, Hsi ED (2007) Cytoplasmic localization of phosphorylated STAT5 in human acute myeloid leukemia is inversely correlated with Flt3-ITD. Blood 110:2775-2776
7. Burns JA, Li Y, Cheney CA, Ou Y, Franlin-Pfeifer LL, Kuklin N, Zhang ZQ (2009) Choice of fixative is crucial to successful immunohistochemical detection of phosphoproteins in paraffinembedded tumor tissues. J Histochem Cytochem 57:257-264
8. Chan WC, Maxwell DJ, Gao X, Bailey RE, Han M, Nie S (2002) Luminescent quantum dots for multiplexed biological detection and imaging. Curr Opin Biotechnol 13:40-46
9. Crossman LC, O'Brien SG (2004) Imatinib therapy in chronic myeloid leukemia. Hematol Oncol Clin North Am 18:605-617
10. Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, Marks C, et al. (2005) Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int J Oncol 27:317-325
11. Espina V, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, Banks S, et al. (2008) A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 7:1998-2018
12. Flaherty KT (2007) Sorafenib in renal cell carcinoma. Clin Cancer Res 13:747s-752s
13. Furukawa Y, Vu HA, Akutsu M, Odgerel T, Izumi T, Tsunoda S, Matsuo Y, et al. (2007) Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. Leukemia 21:1005-1014
14. Gao X, Cui Y, Levenson RM, Chung LW, Nie S (2004) In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22:969-976
15. Gao X, Nie S (2003) Molecular profiling of single cells and tissue specimens with quantum dots. Trends Biotechnol 21:371-373
16. Ghazani AA, Lee JA, Klostranec J, Xiang Q, Dacosta RS,Wilson BC, Tsao MS, et al. (2006) High throughput quantification of protein expression of cancer antigens in tissue microarray using quantum dot nanocrystals. Nano Lett 6:2881-2886
17. Ghosh PM, Malik S, Bedolla R, Kreisberg JI (2003) Akt in prostate cancer: possible role in androgen-independence. Curr Drug Metab 4:487-496
18. Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ, Troyer DA, et al. (2005) Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer 12:119-134
19. Gilliland DG, Griffin JD (2002) Role of FLT3 in leukemia. Curr Opin Hematol 9:274-281
20. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, et al. (2005) The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65:7462-7469
21. Hudelist G, Kostler WJ, Czerwenka K, Kubista E, Attems J, Muller R, Gschwantler-Kaulich D, et al. (2006) Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzuma b-based therapy in patients with metastatic breast cancer. Int J Cancer 118:1126-1134
22. Hunter T (1987) A thousand and one protein kinases. Cell 50:823-829
23. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT, Nolan GP (2004) Single cell profiling of potentiated phosphoprotein networks in cancer cells. Cell 118:217-228
24. Jovin TM (2003) Quantum dots finally come of age. Nat Biotechnol 21:32-33
25. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64:5232-5236
26. Kurosawa M (1994) Phosphorylation and dephosphorylation of protein in regulating cellular function. J Pharmacol Toxicol Methods 31:135-139
27. Lee AV, Taylor ST, Greenall J, Mills JD, Tonge DW, Zhang P, George J, et al. (2003) Rapid induction of IGF-IR signaling in normal and tumor tissue following intravenous injection of IGF-I in mice. Horm Metab Res 35:651-655
28. Lidke DS, Nagy P, Heintzmann R, Arndt-Jovin DJ, Post JN, Grecco HE, Jares-Erijman EA, et al. (2004) Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat Biotechnol 22:198-203
29. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI (2002) Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8:1168-1171
30. Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, et al. (2007) Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol Cancer Ther 6:1070-1078
31. Ono M, Murakami T, Kudo A, Isshiki M, Sawada H, Segawa A (2001) Quantitative comparison of anti-fading mounting media for confocal laser scanning microscopy. J Histochem Cytochem 49:305-312
32. Piloto O, Wright M, Brown P, Kim KT, Levis M, Small D (2007) Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood 109:1643-1652
33. Schiffer CA (2007) BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 357:258-265
34. Slamon D, Pegram M (2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28(suppl 3):13-19
35. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, et al. (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105:54-60
36. Tholouli E, Sweeney E, Barrow E, Clay V, Hoyland JA, Byers RJ (2008) Quantum dots light up pathology. J Pathol 216:275-285
37. True LD, Gao X (2007) Quantum dots for molecular pathology: their time has arrived. J Mol Diagn 9:7-11
38. Wainer H (2006) Finding what is not there through the unfortunate binding the results: the Mendel effect. Chance 19:49-56
39. Zuluaga TT, Hsieh FH, Bodo J, Dong HY, Hsi ED (2007) Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation. Br J Haematol 139:31-40